<DOC>
	<DOCNO>NCT00001630</DOCNO>
	<brief_summary>Platelets particles find along red white blood cell blood play role process blood clotting . Disorders affect platelet low amount platelet blood put patient risk bleeding . The condition low platelet refer thrombocytopenia . Thrombocytopenia associate variety disease include cancer , leukemia , tuberculosis , result autoimmune reaction . Autoimmune reactions disorder normal immune system begin attack . Autoimmune thrombocytopenia ( AITP ) disorder low blood platelet count platelet destroyed antibody produce immune system . Unfortunately , many patient AITP respond standard treatment thrombocytopenia . Cyclophosphamide drug work suppress activity immune system . Researchers believe combine drug transplant rescue blood stem cell may provide effective treatment AITP . The purpose study explore affordability safety therapy treatment AITP . The effectiveness therapy measure number patient whose platelet level rise great 100,000/m3 . If treatment approach appear affordable , study form basis large study compare alternate treatment approach .</brief_summary>
	<brief_title>Treatment Autoimmune Thrombocytopenia ( AITP )</brief_title>
	<detailed_description>Autoimmune Thrombocytopenia ( AITP ) disorder low blood platelet count platelet destruction cause antiplatelet autoantibody . A large proportion patient chronic AITP refractory standard therapy include corticosteroid , immune globulin splenectomy . Cyclophosphamide cytotoxic immunosuppressive agent may induce durable remission refractory autoimmune disease . High-dose cyclophosphamide peripheral blood stem cell ( PBPC ) rescue propose potential definitive therapy AITP ; however , infusion autoreactive lymphocyte could result relapse . The use PBPC deplete T-lymphocytes could circumvent limitation . The purpose phase I/II study explore feasibility safety approach , seek preliminary evidence effectiveness , use high-dose cyclophosphamide ( 50 mg/kg/day x 4 ) follow infusion autologous PBPC enrich CD34+ cell ( concomitantly deplete CD3+ cell ) treatment patient refractory AITP . Safety/feasibility parameter examine include ability mobilize , harvest purify sufficient PBPC yield great 2 x 10 ( 6 ) CD34+ cells/kg ; symptomatic acceptability hematologic toxicity mobilization regimen ( filgrastim 10 micrograms/kg/day IV ) ; tolerability leukapheresis procedure , include central line placement maintenance ; depth duration blood cell nadir follow chemotherapy ; peritransplant bleeding episode transfusion requirement ; episode febrile neutropenia , culture-proven infection antibiotic usage . Effectiveness gauge rapidity number patient achieve complete remission ( platelet count great 100,000/mm ( 3 ) partial remission ( platelet count great 50,000/mm ( 3 ) double platelet count resolution bleed episode ) . Ancillary evidence therapeutic effect seek examine change titer platelet surface glycoprotein antibody . In addition , alteration T-lymphocyte subset examine flow cytometry . If treatment approach appear feasible , study form basis large trial compare alternate treatment approach .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>INCLUSION CRITERIA : Male female , age 1865 year old . Refractory severe chronic autoimmune thrombocytopenia , without autoimmune hemolytic anemia ( Evan 's syndrome ) , follow : 1 . Platelet count frequently 20,000/mm ( 3 ) despite active treatment period great 6 month . 2 . Normal increase megakaryocyte bone marrow aspirate/bx . 3 . No plausible alternative etiology drugmediated thrombocytopenia , marrow failure syndrome thrombocytopenia relate viral bacterial infection . 4 . Failure treatment : i. conventionaldose steroid ( e.g. , prednisone dosage 40 mg/day equivalent , follow dosage taper ) least 3 month . ii . intravenous immunoglobulin . iii . splenectomy . e. Episodic bleeding require transfusion ecchymoses interfere ordinary daily activity . EXCLUSION CRITERIA : ECOG performance status great 1 . Cardiopulmonary disease include : 1 . History coronary artery disease , angina pectoris congestive heart failure . 2 . LV ejection fraction le 40 percent 2D echocardiogram . Renal disease , serum creatinine great 2.5 mg/dL creatinine clearance le 30 mL/min . Significant hepatic dysfunction , bilirubin great 2 mg/dL transaminase great 2 time UNL . Uncorrected coagulopathy . Bone marrow aplasia ( cellularity le 10 percent ) , single multilineage hematopoietic failure , myelodysplastic syndrome , extensive marrow fibrosis . History active diagnosis malignancy ( except treat nonmelanoma skin cancer cevical carcinoma situ ) . HIV positive . Pregnancy lactation , unwillingness practice adequate birth control peritransplant period . Psychiatric illness mental incapacity understand give inform consent . Other medical illness condition , opinion Investigators , may contraindicate participation study due patient ' risk compromise study integrity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 21, 2011</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Evan 's Syndrome</keyword>
	<keyword>Autoimmune Hemolytic Anemia</keyword>
	<keyword>Episodic Bleeding</keyword>
</DOC>